MarketScreener Editorial Features United Therapeutics Corporation
Equities
UTHR
US91307C1027
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 294.42 USD | +1.39% |
|
+1.21% | -16.56% |
| 06-30 | United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says | MT |
| 06-30 | UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating | MT |
MarketScreener Editorial Features
Search
 | United Therapeutics delivers 18th consecutive quarter of topline growth | June 17, 2025 at 11:16 am |
 | Stocks in motion: Intuit and Axon rise on great results, Applovin tumbles on short-seller attack | February 26, 2025 at 03:36 pm |
 | Everything's going according to plan | July 11, 2024 at 02:51 pm |
 | Analyst recommendations: Albemarle, Levi Strauss & Co, On Semiconductor, Spotify, Costco... | July 11, 2024 at 10:16 am |
 | Better days ahead? | December 05, 2022 at 04:06 pm |
 | Analyst recommendations: Burberry, Comcast, Starbucks, SVB Financial, Warner Music... | December 05, 2022 at 10:48 am |
 | Today on Wall Street: This is the real test | October 18, 2021 at 03:36 pm |
No results for this search
- Stock Market
- Equities
- UTHR Stock
- News United Therapeutics Corporation
- MarketScreener Editorial Features
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition